相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
Sudhir Kumar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Pomalidomide-based therapy for extramedullary multiple myeloma
Yating Li et al.
HEMATOLOGY (2022)
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios Dimopoulos et al.
BLOOD (2021)
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
Jiri Minarik et al.
BMC CANCER (2021)
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
Elena Zamagni et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Sophia Danhof et al.
ANNALS OF HEMATOLOGY (2021)
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells
David J. DiLillo et al.
BLOOD ADVANCES (2021)
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Laura Rosinol et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Shih-Feng Cho et al.
CANCERS (2021)
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
Haobin Deng et al.
FRONTIERS IN IMMUNOLOGY (2021)
Extramedullary disease in multiple myeloma
Radhika Bansal et al.
BLOOD CANCER JOURNAL (2021)
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Vittorio Montefusco et al.
HAEMATOLOGICA (2020)
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
Meral Beksac et al.
HAEMATOLOGICA (2020)
A case of myelomatous pleural effusion: an unusual onset of multiple myeloma
Alicia Martinez-Iribarren et al.
BLOOD (2020)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
Xiang Zhou et al.
CANCERS (2020)
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Meletios A. Dimopoulos et al.
BLOOD CANCER JOURNAL (2020)
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study
Maxime Jullien et al.
ANNALS OF HEMATOLOGY (2019)
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed/refractory multiple myeloma
Raquel Jimenez-Segura et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
Eric L. Smith et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Nico Gagelmann et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Dennis Cooper et al.
BLOOD (2019)
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas
Andrew J. Yee et al.
BLOOD (2019)
Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature
Uday Yanamandra et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy
Sophia Danhof et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
Marjorie Pick et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann et al.
HAEMATOLOGICA (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann et al.
HAEMATOLOGICA (2018)
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Nizar J. Bahlis et al.
BLOOD (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab
Ezzat Elhassadi et al.
CLINICAL CASE REPORTS (2018)
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma
Arjun Lakshman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The possible role of burden of therapy on the risk of myeloma extramedullary spread
Silvia Mangiacavalli et al.
ANNALS OF HEMATOLOGY (2017)
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Michele Cavo et al.
LANCET ONCOLOGY (2017)
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy
David Dingli et al.
MAYO CLINIC PROCEEDINGS (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome
L. Kumar et al.
BONE MARROW TRANSPLANTATION (2017)
Marizomib for central nervous system-multiple myeloma
Ashraf Badros et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study
Eli Muchtar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier
Kaijun Di et al.
NEURO-ONCOLOGY (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
P. G. Richardson et al.
BLOOD (2016)
Myelomatous Involvement of the Central Nervous System
Jonas Paludo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Survival of Effector CD8+ T Cells during Influenza Infection Is Dependent on Autophagy
Katrin Schlie et al.
JOURNAL OF IMMUNOLOGY (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma
Sung-Eun Lee et al.
ANNALS OF HEMATOLOGY (2015)
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
Ludek Pour et al.
HAEMATOLOGICA (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Autologous stem cell transplant can overcome poor prognosis in patients with multiple myeloma with extramedullary plasmacytoma
Jian Li et al.
LEUKEMIA & LYMPHOMA (2014)
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents
Christine I. Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models
Zhimin Li et al.
PLOS ONE (2013)
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients
Alessandro Gozzetti et al.
CANCER (2012)
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates
Jodi A. Muscal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Response to Low-dose Bortezomib in Plasma Cell Leukemia Patients with Malignant Pleural Effusion and Ascites: A Case Report and a Review of the Literature
Yasunobu Sekiguchi et al.
INTERNAL MEDICINE (2012)
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
Heather Landau et al.
LEUKEMIA & LYMPHOMA (2012)
Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma
Jose M. Calvo-Villas et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients
Adrian Alegre et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
Joan Blade et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
K. Detweiler Short et al.
LEUKEMIA (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
M. Varettoni et al.
ANNALS OF ONCOLOGY (2010)
The impact of extramedullary disease at presentation on the outcome of myeloma
Ping Wu et al.
LEUKEMIA & LYMPHOMA (2009)
Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma
Jan Cerny et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Use of intrapleural bortezomib in myelomatous pleural effusion
Emilio Iannitto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib
Alex Hemeryck et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D. Chauhan et al.
ONCOGENE (2007)
Bortezomib:: an effective agent in extramedullary disease in multiple myeloma
R Laura et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Thalidomide for the treatment of leptomeningeal multiple myeloma
Y Hattori et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib
MT Krauth et al.
LEUKEMIA RESEARCH (2005)
Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect
E Paubelle et al.
LEUKEMIA (2005)
Discordant response or progression in patients with myeloma treated with thalidomide-based regimens
A Anagnostopoulos et al.
LEUKEMIA & LYMPHOMA (2004)
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma
A Avigdor et al.
LEUKEMIA & LYMPHOMA (2001)
Thalidomide in multiple myeloma:: lack of response of soft-tissue plasmacytomas
J Bladé et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
